Apple sues Masimo, says the medical tech company “carefully studied Apple's IP” during its patent-infringement suit against Apple in order to make its W1 watch
Apple Inc sued medical technology company Masimo Corp in Delaware federal court on Thursday, accusing its new W1 line …
Context & Ripple Effects
This countersuit inverts the arc that began when Masimo filed its 2020 patent suit accusing Apple of stealing blood-oxygen and heart-rate monitoring tech. Since then the dispute has run against Apple: an ITC judge found some Apple Watches infringe one of five Masimo pulse-oximeter patents, Apple fought the resulting import ban on appeal, and a California jury later hit Apple with a $634M verdict.
Apple's Delaware filing reframes Masimo from plaintiff to alleged copyist — claiming Masimo 'carefully studied' Apple's IP during the litigation itself to build its W1 watch line. It matters because it converts a defensive patent fight into a two-front war over who owns health-sensor innovation.
First-order effects
- Masimo now defends its W1 watch line on a second legal front while pursuing claims against Apple, splitting its litigation resources and exposing its consumer-hardware push to infringement counterclaims.
- Apple gains negotiating leverage: with an ITC import ban, an appeal, and a $634M damages verdict already in play, a countersuit gives it a claim to trade in any settlement talks.
Second-order effects
- Masimo's pivot from medical devices into consumer wearables gets costlier — every W1 feature now carries litigation risk that could force design changes, licensing fees, or delayed launches.
- Other medical-device makers eyeing the smartwatch market see the template: entering Apple's territory invites not just defense but offensive countersuits, raising the bar for health-tech entrants.
Third-order effects
- If mutual-suit patterns like this hold, health-sensor IP between medical-device firms and consumer-wearable giants trends toward cross-licensing blocs rather than clean winner-take-all verdicts.
- Litigation itself becomes an IP battleground — each side's filings and discovery feed the other's product roadmap, entrenching big players who can sustain multi-year, multi-front patent wars.
The trend: Health-monitoring patents are pulling medical-device makers and consumer-wearable giants into escalating mutual litigation, where each lawsuit doubles as ammunition for the next.